Ipafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Ipafricept. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Ipafricept. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Ipafricept. |
| Estrone | Estrone may increase the thrombogenic activities of Ipafricept. |
| Estradiol | Estradiol may increase the thrombogenic activities of Ipafricept. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Ipafricept. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Ipafricept. |
| Mestranol | Mestranol may increase the thrombogenic activities of Ipafricept. |
| Estriol | Estriol may increase the thrombogenic activities of Ipafricept. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Ipafricept. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Ipafricept. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Ipafricept. |
| Tibolone | Tibolone may increase the thrombogenic activities of Ipafricept. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ipafricept. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ipafricept. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Ipafricept. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Ipafricept. |
| Zeranol | Zeranol may increase the thrombogenic activities of Ipafricept. |
| Equol | Equol may increase the thrombogenic activities of Ipafricept. |
| Promestriene | Promestriene may increase the thrombogenic activities of Ipafricept. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Ipafricept. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Ipafricept. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Ipafricept. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Ipafricept. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Ipafricept. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Ipafricept. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Ipafricept. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Ipafricept. |
| Formononetin | Formononetin may increase the thrombogenic activities of Ipafricept. |
| Estetrol | Estetrol may increase the thrombogenic activities of Ipafricept. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Ipafricept. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ipafricept. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Ipafricept. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Ipafricept. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Ipafricept. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ipafricept. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ipafricept. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Ipafricept. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ipafricept. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Ipafricept. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Ipafricept. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Ipafricept. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ipafricept. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ipafricept. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Ipafricept. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipafricept. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ipafricept. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Ipafricept. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ipafricept. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Ipafricept. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Ipafricept. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Ipafricept. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ipafricept. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ipafricept. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Ipafricept. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Ipafricept. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Ipafricept. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Ipafricept. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Ipafricept. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Ipafricept. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Ipafricept. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Ipafricept. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Ipafricept. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Ipafricept. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Ipafricept. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Ipafricept. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Ipafricept. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Ipafricept. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Ipafricept. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Ipafricept. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Ipafricept. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Ipafricept. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Ipafricept. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Ipafricept. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Ipafricept. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Ipafricept. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Ipafricept. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Ipafricept. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Ipafricept. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Ipafricept. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Ipafricept. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Ipafricept. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Ipafricept. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Ipafricept. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Ipafricept. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Ipafricept. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Ipafricept. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ipafricept. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Ipafricept. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Ipafricept. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Ipafricept. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Ipafricept. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Ipafricept. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Ipafricept. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Ipafricept. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Ipafricept. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ipafricept. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Ipafricept. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Ipafricept. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Ipafricept. |